Base de dados : MEDLINE
Pesquisa : D09.698.373.400.320 [Categoria DeCS]
Referências encontradas : 590 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 59 ir para página                         

  1 / 590 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566581
[Au] Autor:Manabe H; Nozawa A; Matsumoto M; Ohtani M
[Ad] Endereço:Division of Hospital Pharmacy, Tokyo Postal Services Agency Hospital.
[Ti] Título:Evaluation of Moisturizing Effect of Heparinoid Ointment (Hirudoid Soft Ointment) Diluted by White Petrolatum (Propeto).
[So] Source:Yakugaku Zasshi;137(6):763-766, 2017.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Steroid ointments are frequently mixed with moisturizer. It was reported that steroid ointments mixed with moisturizer increase permeability. There are only few studies done on the permeability of the moisturizer. We researched moisturizing effect of heparinoid ointment (Hirudoid Soft ointment) diluted with white petrolatum (Propeto) on the dry skin models by measuring water content of stratum. Two to four fold dilution of Hirudoid to white petrolatum resulted in a significant decrease in the moisturizing effect of the active ingredient. There was no significant difference in moisturizing effect between four times diluted mixture and white petrolatum alone. This leads to the conclusion that steroid ointment mixture with moisturizer is frequently used, but we should take more caution regarding the decrease of moisturizing effect.
[Mh] Termos MeSH primário: Água Corporal/metabolismo
Heparinoides/química
Heparinoides/farmacologia
Bases para Pomadas
Vaselina/química
Vaselina/farmacologia
Pele/metabolismo
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Condutividade Elétrica
Feminino
Heparinoides/administração & dosagem
Seres Humanos
Masculino
Pomadas
Vaselina/administração & dosagem
Fenômenos Fisiológicos da Pele
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heparinoids); 0 (Ointment Bases); 0 (Ointments); 8009-03-8 (Petrolatum)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.16-00191


  2 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28374884
[Au] Autor:Sandercock PA; Leong TS
[Ad] Endereço:Centre for Clinical Brain Sciences (CCBS), University of Edinburgh, The Chancellor's Building, 49 Little France Crescent, Edinburgh, UK, EH16 4SB.
[Ti] Título:Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
[So] Source:Cochrane Database Syst Rev;4:CD000119, 2017 04 04.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Low-molecular-weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the original Cochrane Review of these agents, first published in 2001 and last updated in 2008. OBJECTIVES: To determine whether antithrombotic therapy with LMWHs or heparinoids is associated with a reduction in the proportion of people who are dead or dependent for activities in daily living compared with UFH. SEARCH METHODS: We searched the Cochrane Stroke Group Trials Register (last searched February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL: the Cochrane Library Issue 1, 2017), MEDLINE (1966 to February 2017), and Embase (1980 to February 2017). We also searched trials registers to February 2017: ClinicalTrials.gov, EU Clinical Trials Register, Stroke Trials Registry, ISRCTN Registry and the World Health Organization (WHO) International Clinical Trials Registry Platform. SELECTION CRITERIA: Unconfounded randomised trials comparing LMWH or heparinoids with standard UFH in people with acute ischaemic stroke, in which participants were recruited within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently chose studies for inclusion, assessed risk of bias and trial quality, extracted and analysed the data. Differences were resolved by discussion. MAIN RESULTS: We included nine trials involving 3137 participants. We did not identify any new trials for inclusion in this updated review. None of the studies reported data on the primary outcome in sufficient detail to enable analysis for the review. Overall, there was a moderate risk of bias in the included studies. Compared with UFH, there was no evidence of an effect of LMWH or heparinoids on death from all causes during the treatment period (96/1616 allocated LMWH/heparinoid versus 78/1486 allocated UFH; odds ratio (OR) 1.06, 95% CI 0.78 to 1.47; 8 trials, 3102 participants, low quality evidence). LMWH or heparinoid were associated with a significant reduction in deep vein thrombosis (DVT) compared with UFH (OR 0.55, 95% CI 0.44 to 0.70, 7 trials, 2585 participants, low quality evidence). However, the number of the major clinical events such as pulmonary embolism (PE) and intracranial haemorrhage was too small to provide a reliable estimate of the effects. AUTHORS' CONCLUSIONS: Treatment with a LMWH or heparinoid after acute ischaemic stroke appears to decrease the occurrence of DVT compared with standard UFH, but there are too few data to provide reliable information on their effects on other important outcomes, including functional outcome, death and intracranial haemorrhage.
[Mh] Termos MeSH primário: Anticoagulantes/uso terapêutico
Fibrinolíticos/uso terapêutico
Heparina de Baixo Peso Molecular/uso terapêutico
Heparinoides/uso terapêutico
Acidente Vascular Cerebral/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Isquemia Encefálica/tratamento farmacológico
Causas de Morte
Hemorragia/induzido quimicamente
Hemorragia/epidemiologia
Heparina/uso terapêutico
Seres Humanos
Embolia Pulmonar/epidemiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Acidente Vascular Cerebral/mortalidade
Trombose Venosa/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Fibrinolytic Agents); 0 (Heparin, Low-Molecular-Weight); 0 (Heparinoids); 9005-49-6 (Heparin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000119.pub4


  3 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28256735
[Au] Autor:Mozafari M; Balasupramaniam S; Preu L; El Deeb S; Reiter CG; Wätzig H
[Ad] Endereço:Institute of Medicinal and Pharmaceutical Chemistry, TU Braunschweig, Braunschweig, Germany.
[Ti] Título:Using affinity capillary electrophoresis and computational models for binding studies of heparinoids with p-selectin and other proteins.
[So] Source:Electrophoresis;38(12):1560-1571, 2017 06.
[Is] ISSN:1522-2683
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A fast and precise affinity capillary electrophoresis (ACE) method has been developed and applied for the investigation of the binding interactions between P-selectin and heparinoids as potential P-selectin inhibitors in the presence and absence of calcium ions. Furthermore, model proteins and vitronectin were used to appraise the binding behavior of P-selectin. The normalized mobility ratios (∆R/R ), which provided information about the binding strength and the overall charge of the protein-ligand complex, were used to evaluate the binding affinities. It was found that P-selectin interacts more strongly with heparinoids in the presence of calcium ions. P-selectin was affected by heparinoids at the concentration of 3 mg/L. In addition, the results of the ACE experiments showed that among other investigated proteins, albumins and vitronectin exhibited strong interactions with heparinoids. Especially with P-selectin and vitronectin, the interaction may additionally induce conformational changes. Subsequently, computational models were applied to interpret the ACE experiments. Docking experiments explained that the binding of heparinoids on P-selectin is promoted by calcium ions. These docking models proved to be particularly well suited to investigate the interaction of charged compounds, and are therefore complementary to ACE experiments.
[Mh] Termos MeSH primário: Heparinoides/química
Selectina-P/química
Proteínas/química
[Mh] Termos MeSH secundário: Sítios de Ligação
Cálcio
Simulação por Computador
Eletroforese Capilar
Íons
Ligantes
Protaminas/química
Ligação Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Heparinoids); 0 (Ions); 0 (Ligands); 0 (P-Selectin); 0 (Protamines); 0 (Proteins); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1002/elps.201600480


  4 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28209294
[Au] Autor:Horigome T; Takumi S; Shirai K; Kido T; Hagiwara-Chatani N; Nakashima A; Adachi N; Yano H; Hirai Y
[Ad] Endereço:Department of Biomedical Chemistry, Graduate school of Science and Technology, Kwansei Gakuin University, 2-1, Gakuen, Sanda 669-1337, Japan.
[Ti] Título:Sulfated glycosaminoglycans and non-classically secreted proteins, basic FGF and epimorphin, coordinately regulate TGF-ß-induced cell behaviors of human scar dermal fibroblasts.
[So] Source:J Dermatol Sci;86(2):132-141, 2017 May.
[Is] ISSN:1873-569X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Upon skin injuries, dermal fibroblasts actively produce transforming growth factor-ß (TGF-ß), which leads to the formation of α-smooth muscle actin (αSMA)-positive granulation tissues. The hyperplasia or incomplete regression of these tissues subsequently causes scar formation in the skin, where sulfated glycosaminoglycans (GAGs), side chains of unique proteoglycans, are supposed to play important roles. OBJECTIVE: The aim of this study is to clarify the effects of sulfated GAGs on dermal cell behaviors triggered by the TGF-ß signaling, along with its possible regulators basic fibroblast growth factor (bFGF) and cell surface epimorphin. bFGF and epimorphin might regulate the TGF-ß-induced αSMA expression, they could exert such effects only in specific cellular contexts, given that they lack conventional signal sequences for extracellular localization. METHODS: Human scar-derived dermal fibroblasts (HSFs) were treated with TGF-ß alone, TGF-ß plus bFGF, and TGF-ß plus cell surface expression of epimorphin. The effects of GAGs on the expression of αSMA and the cellular morphology were then investigated. RESULTS: A highly sulfated chondroitin sulfate (CS-E) or its substitute (heparinoid) had marked inhibitory effects on TGF-ß-mediated changes in HSF behaviors. We found that heparinoid can directly associate with TGF-ß, bFGF and epimorphin. We also found that bFGF downregulated αSMA, which was attenuated by heparinoid, whereas epimorphin augmented αSMA expression, which was further amplified by heparinoid. CONCLUSIONS: TGF-ß, bFGF and epimorphin in the extracellular microenvironment cooperatively affect HSF behaviors under the control of a highly sulfated chondroitin sulfate. These results provide important evidence towards understanding the regulation of TGF-ß-induced HSF behaviors.
[Mh] Termos MeSH primário: Cicatriz/metabolismo
Fibroblastos/metabolismo
Glicosaminoglicanos/química
Proteoglicanas/metabolismo
Sintaxina 1/metabolismo
Fator de Crescimento Transformador beta/farmacologia
[Mh] Termos MeSH secundário: Actinas/metabolismo
Animais
Células COS
Membrana Celular/metabolismo
Cercopithecus aethiops
Sulfatos de Condroitina/química
Fator 2 de Crescimento de Fibroblastos/farmacologia
Heparinoides/metabolismo
Seres Humanos
Proteínas Recombinantes/farmacologia
Transdução de Sinais
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Actins); 0 (Glycosaminoglycans); 0 (Heparinoids); 0 (Proteoglycans); 0 (Recombinant Proteins); 0 (STX2 protein, human); 0 (Syntaxin 1); 0 (Transforming Growth Factor beta); 103107-01-3 (Fibroblast Growth Factor 2); 9007-28-7 (Chondroitin Sulfates)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170218
[St] Status:MEDLINE


  5 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27725389
[Au] Autor:Sugiyama I; Takahashi N; Sadzuka Y
[Ad] Endereço:School of Pharmacy, Iwate Medical University.
[Ti] Título:Effect of Mixing Time and Storage Condition on Characterization of Heparinoid Admixtures with Corticosteroids.
[So] Source:Yakugaku Zasshi;136(10):1391-1400, 2016.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:In dermatologic therapy, several external preparations formulated as ointments or creams are prescribed. And they are often admixture to improve patient compliance. In this study, we prepared admixtures of moisturizer with steroids and examined their usability and the amount of principal agent in formulations, particularly focusing on the moisturizer content. Four heparinoid semisolid formulations were selected: Hirudoid soft ointment 0.3% (Formulation A) and 3 generic agents [(Besoften oil-based cream 0.3% (Formulation B), Kuradoido ointment 0.3% (Formulation C), and Hepadaerm ointment 0.3% (Formulation D)], and Antebate ointment 0.05% (Formulation E) were used as steroids. Formulation A and B are water-in-oil emulsions, and Formulation C and D are oil-in-water emulsions. Admixtures looked like to be mixed uniformly by visual observation. In the examination of heparinoid amount, admixture A+E and B+E were mixed uniformly. On the other hand, admixture C+E was remarkable un-uniformly. It was speculated that the emulsification of formulation C was broken. The phenomenon was supported by the result of malleability. After 8 weeks storage, the heparinoid ratio in each formulation could be expressed as follows: Admixture B≥Admixture A>Admixture C=Admixture D. A suitable storage temperature was 4°C. The results of physicochemical data analysis reveal the formulations composed of water-in-oil cream, i.e., Formulation A and Formulation B, to be the optimal choices for mixing with steroid ointments. Mixing time and storage conditions may be optimized to solve pharmaceutical problems. Moreover, understanding the emulsion type and character of semisolid formulations can expand the range of formulation options.
[Mh] Termos MeSH primário: Corticosteroides
Composição de Medicamentos/métodos
Armazenamento de Medicamentos
Heparinoides
[Mh] Termos MeSH secundário: Fenômenos Químicos
Emulsões
Óleos
Pomadas
Fatores de Tempo
Viscosidade
Água
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Emulsions); 0 (Heparinoids); 0 (Oils); 0 (Ointments); 059QF0KO0R (Water)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161012
[St] Status:MEDLINE


  6 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26937941
[Au] Autor:Durila M; Pavlicek P; Hadacova I; Nahlovsky J; Janeckova D
[Ad] Endereço:From the Department of Anesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol (MD, PP), Department of Clinical Haematology, Motol University Hospital (IH), Department of Paedriatric Surgery (JN), and Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic (DJ).
[Ti] Título:Endogenous Heparinoids May Cause Bleeding in Mucor Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report.
[So] Source:Medicine (Baltimore);95(8):e2933, 2016 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mucormycosis is an aggressive fungal infection, which invades endothelial cells of blood vessels. This condition might lead to destruction of endothelium and release of heparin-like substances to the bloodstream and cause life-threatening bleeding, which is not well described in the literature.We present a patient with mucormycosis who experienced life-threatening bleeding, although no standard laboratory test could detect any coagulopathy.The cause of bleeding-coagulopathy was detected only by nonactivated thromboelastometry (NATEM), which revealed the presence of heparin-like substances. After treatment with recombinant activated FVII rotational thromboelastometry, results improved and the patient stopped bleeding. Regular application of the drug was necessary during acute phase of infection to prevent further bleeding.In this case report, we show that NATEM can detect the presence of heparin-like substances in bleeding patient with mucormycosis infection and that recombinant activated FVII can be used to stop and prevent bleeding until infection resolves.
[Mh] Termos MeSH primário: Testes de Coagulação Sanguínea
Fator VIIa/uso terapêutico
Hemorragia/terapia
Heparinoides/metabolismo
Mucormicose/tratamento farmacológico
[Mh] Termos MeSH secundário: Antifúngicos/uso terapêutico
Criança
Drenagem/efeitos adversos
Feminino
Hemorragia/etiologia
Seres Humanos
Doença Iatrogênica
Mucormicose/metabolismo
Proteínas Recombinantes/uso terapêutico
Baço/lesões
Baço/cirurgia
Esplenectomia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Heparinoids); 0 (Recombinant Proteins); AC71R787OV (recombinant FVIIa); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160304
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000002933


  7 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26874675
[Au] Autor:Poppelaars F; Damman J; de Vrij EL; Burgerhof JG; Saye J; Daha MR; Leuvenink HG; Uknis ME; Seelen MA
[Ad] Endereço:Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groninge, Groningen.
[Ti] Título:New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.
[So] Source:Clin Exp Immunol;184(3):378-88, 2016 Jun.
[Is] ISSN:1365-2249
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Complement activation is of major importance in numerous pathological conditions. Therefore, targeted complement inhibition is a promising therapeutic strategy. C1-esterase inhibitor (C1-INH) controls activation of the classical pathway (CP) and the lectin pathway (LP). However, conflicting data exist on inhibition of the alternative pathway (AP) by C1-INH. The inhibitory capacity of C1-INH for the CP is potentiated by heparin and other glycosaminoglycans, but no data exist for the LP and AP. The current study investigates the effects of C1-INH in the presence or absence of different clinically used heparinoids on the CP, LP and AP. Furthermore, the combined effects of heparinoids and C1-INH on coagulation were investigated. C1-INH, heparinoids or combinations were analysed in a dose-dependent fashion in the presence of pooled serum. Functional complement activities were measured simultaneously using the Wielisa(®) -kit. The activated partial thrombin time was determined using an automated coagulation analyser. The results showed that all three complement pathways were inhibited significantly by C1-INH or heparinoids. Next to their individual effects on complement activation, heparinoids also enhanced the inhibitory capacity of C1-INH significantly on the CP and LP. For the AP, significant potentiation of C1-INH by heparinoids was found; however, this was restricted to certain concentration ranges. At low concentrations the effect on blood coagulation by combining heparinoids with C1-INH was minimal. In conclusion, our study shows significant potentiating effects of heparinoids on the inhibition of all complement pathways by C1-INH. Therefore, their combined use is a promising and a potentially cost-effective treatment option for complement-mediated diseases.
[Mh] Termos MeSH primário: Ativação do Complemento/efeitos dos fármacos
Proteína Inibidora do Complemento C1/farmacologia
Heparinoides/farmacologia
[Mh] Termos MeSH secundário: Coagulação Sanguínea/efeitos dos fármacos
Via Alternativa do Complemento/efeitos dos fármacos
Via Clássica do Complemento/efeitos dos fármacos
Lectina de Ligação a Manose da Via do Complemento/efeitos dos fármacos
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Sinergismo Farmacológico
Seres Humanos
Tempo de Tromboplastina Parcial
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement C1 Inhibitor Protein); 0 (Drug Combinations); 0 (Heparinoids)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160215
[St] Status:MEDLINE
[do] DOI:10.1111/cei.12777


  8 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26672027
[Au] Autor:Mulloy B; Hogwood J; Gray E; Lever R; Page CP
[Ad] Endereço:Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United Kingdom (B.M., C.P.P.); National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom (J.H., E.G.); and University College London School of Ph
[Ti] Título:Pharmacology of Heparin and Related Drugs.
[So] Source:Pharmacol Rev;68(1):76-141, 2016 Jan.
[Is] ISSN:1521-0081
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Heparin has been recognized as a valuable anticoagulant and antithrombotic for several decades and is still widely used in clinical practice for a variety of indications. The anticoagulant activity of heparin is mainly attributable to the action of a specific pentasaccharide sequence that acts in concert with antithrombin, a plasma coagulation factor inhibitor. This observation has led to the development of synthetic heparin mimetics for clinical use. However, it is increasingly recognized that heparin has many other pharmacological properties, including but not limited to antiviral, anti-inflammatory, and antimetastatic actions. Many of these activities are independent of its anticoagulant activity, although the mechanisms of these other activities are currently less well defined. Nonetheless, heparin is being exploited for clinical uses beyond anticoagulation and developed for a wide range of clinical disorders. This article provides a "state of the art" review of our current understanding of the pharmacology of heparin and related drugs and an overview of the status of development of such drugs.
[Mh] Termos MeSH primário: Anticoagulantes/farmacologia
Heparina/farmacologia
[Mh] Termos MeSH secundário: Anti-Inflamatórios/farmacologia
Anticoagulantes/efeitos adversos
Antineoplásicos/farmacologia
Antivirais/farmacologia
Moléculas de Adesão Celular/metabolismo
Quimiocinas/metabolismo
Proteínas do Sistema Complemento/metabolismo
Citocinas/metabolismo
Heparina/efeitos adversos
Heparina de Baixo Peso Molecular/farmacologia
Heparinoides/farmacologia
Seres Humanos
Peptídeos e Proteínas de Sinalização Intercelular/metabolismo
Agregados Proteicos/fisiologia
Selectinas/metabolismo
Venenos de Serpentes/metabolismo
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Anticoagulants); 0 (Antineoplastic Agents); 0 (Antiviral Agents); 0 (Cell Adhesion Molecules); 0 (Chemokines); 0 (Cytokines); 0 (Heparin, Low-Molecular-Weight); 0 (Heparinoids); 0 (Intercellular Signaling Peptides and Proteins); 0 (Protein Aggregates); 0 (Selectins); 0 (Snake Venoms); 9005-49-6 (Heparin); 9007-36-7 (Complement System Proteins)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151216
[Lr] Data última revisão:
151216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151217
[St] Status:MEDLINE
[do] DOI:10.1124/pr.115.011247


  9 / 590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26572396
[Au] Autor:Wu J; Zhang M; Zhang Y; Zeng Y; Zhang L; Zhao X
[Ad] Endereço:Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
[Ti] Título:Anticoagulant and FGF/FGFR signal activating activities of the heparinoid propylene glycol alginate sodium sulfate and its oligosaccharides.
[So] Source:Carbohydr Polym;136:641-8, 2016 Jan 20.
[Is] ISSN:1879-1344
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Propylene glycol alginate sodium sulfate (PSS), prepared by chemical sulfation of alginate, has been used for treating cardiovascular diseases in China for nearly 30 years. In the current study, the PSS was hydrolyzed partially by an environment-friendly solid phase acid degradation method, and then separated by using a Bio-Gel P6 chromatographic column. Thirteen PSS oligosaccharide fractions were obtained and characterized by ESI-MS. The results of different coagulation assays showed that a high molecular weight and a higher degree of sulfation were essential for the anticoagulant activity of the PSS because the PSS oligosaccharides exhibited no detectable anticoagulant activity. In contrast, not only PSS but also certain oligosaccharides showed significant activities in stimulation of FGF1, 2, 7, 8, 9 or 10 induced cell proliferation in FGFR1c-expressing BaF3 cells. Such properties made the PSS and its oligosaccharides promising compounds in the regulation of FGF-dependent development, treatment of cancer, and wound healing processes.
[Mh] Termos MeSH primário: Alginatos/química
Anticoagulantes/química
Fatores de Crescimento de Fibroblastos/metabolismo
Heparinoides/química
Receptores de Fatores de Crescimento de Fibroblastos/metabolismo
[Mh] Termos MeSH secundário: Animais
Anticoagulantes/farmacologia
Linhagem Celular
Proliferação Celular/efeitos dos fármacos
Células Cultivadas
Heparinoides/farmacologia
Camundongos
Oligossacarídeos/química
Oligossacarídeos/farmacologia
Ovinos
Transdução de Sinais/efeitos dos fármacos
Sulfatos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Alginates); 0 (Anticoagulants); 0 (Heparinoids); 0 (Oligosaccharides); 0 (Receptors, Fibroblast Growth Factor); 0 (Sulfates); 0YPR65R21J (sodium sulfate); 26CD3J2R0C (propylene glycol alginate ester); 62031-54-3 (Fibroblast Growth Factors)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:161126
[Lr] Data última revisão:
161126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151118
[St] Status:MEDLINE


  10 / 590 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26473371
[Au] Autor:Nongnuch A; Tangsujaritvijit V; Davenport A
[Ad] Endereço:Renal Unit, Department of Medicine Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand - oatega@yahoo.com.
[Ti] Título:Anticoagulation for renal replacement therapy for patients with acute kidney injury.
[So] Source:Minerva Urol Nefrol;68(1):87-104, 2016 Feb.
[Is] ISSN:1827-1758
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Patients with acute kidney injury are generally prothrombotic, and as such prone to increased risk of clotting in extracorporeal renal replacement therapy (RRT) circuits. Although some patients may be adequately treated by intermittent RRT, however due to cardiovascular instability many patients are treated by continuous renal replacement therapy (CCRT) or prolonged intermittent renal replacement therapy (PIRRT). Clotting in the RRT circuit not only reduces the efficiency of solute clearances, affects fluid balance, but also has economic health care costs. The longer duration RRT modes, CRRT and PIRRT are more prone to clotting, and more dependent on adequate anticoagulation. This review will compare the currently available systemic and regional anticoagulation options for CRRT and PIRRT for the patient with acute kidney injury.
[Mh] Termos MeSH primário: Lesão Renal Aguda/terapia
Anticoagulantes/uso terapêutico
Terapia de Substituição Renal
[Mh] Termos MeSH secundário: Lesão Renal Aguda/mortalidade
Antitrombinas/uso terapêutico
Ácido Cítrico/uso terapêutico
Heparina/análogos & derivados
Heparina/uso terapêutico
Heparina de Baixo Peso Molecular/uso terapêutico
Heparinoides/uso terapêutico
Seres Humanos
Unidades de Terapia Intensiva
Prostaglandinas/uso terapêutico
Inibidores de Serino Proteinase/uso terapêutico
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Antithrombins); 0 (Heparin, Low-Molecular-Weight); 0 (Heparinoids); 0 (Prostaglandins); 0 (Serine Proteinase Inhibitors); 129480-74-6 (ITF 300); 2968PHW8QP (Citric Acid); 9005-49-6 (Heparin)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170126
[Lr] Data última revisão:
170126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151017
[St] Status:MEDLINE



página 1 de 59 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde